OK to enter
06/07/04
DC

AMENDMENTS TO THE CLAIMS

I. Listing of the Claims: This Listing will replace all prior versions and listings of claims in the application:

1. (Currently amended) A method for assessing risk of Alzheimer's Disease ~~a neurodegenerative disease or disorder associated with amyloidosis~~ in a subject, which method comprises:

determining a level of anti-ß-amyloid-42 ($A\beta_{42}$) antibody in a biological sample selected from the group consisting of blood, serum, and plasma ~~and cerebral spinal fluid~~ from a subject,

comparing the level of anti-$A\beta_{42}$ antibody in the biological sample from the subject to a normal level determined from an average of the level of anti-$A\beta_{42}$ antibody in a biological sample from a population consisting of age-matched normal subjects who do not show any symptoms of neurodegenerative disease or disorder associated with amyloidosis, wherein a lower level in the biological sample from the subject indicates the risk Alzheimer's Disease ~~of a neurodegenerative disease or disorder associated with amyloidosis~~.

2. - 4. (Canceled).

2 ~~5.~~ (Original) The method according to claim 1, which comprises determining the level of anti-$A\beta_{42}$ antibody in the biological sample by immunoassay.

3 ~~6.~~ (Original) The method according to claim ~~5~~ 2, wherein the immunoassay is an enzyme-linked immunosorbent assay.

7. (Cancelled).

4 ~~8.~~ (Previously Presented) The method according to claim 1, wherein the subject is from a family that has a member or members with familial Alzheimer's Disease.

5 ~~9.~~ (Previously Presented) The method according to claim 1, wherein the subject is in his or her seventh or eighth decade of life.

10. - 15. (Canceled).

16. (Currently amended) A method for assessing risk of Alzheimer's Disease in a subject, which method comprises:

determining a level of anti-ß-amyloid-42 ($A\beta_{42}$) antibody in a biological sample selected from the group consisting of blood, serum, and plasma ~~and cerebral spinal fluid~~ from a subject, wherein the subject does not exhibit symptoms of cognitive dysfunction or memory dysfunction,

comparing a level of anti-$A\beta_{42}$ antibody in a biological sample, to a normal level determined from an average of the level of anti-$A\beta_{42}$ antibody in a biological sample from a population consisting of age-matched normal subjects who do not show any symptoms of associated with Alzheimer's Disease, wherein a lower level in the biological sample from the subject indicates the risk of Alzheimer's Disease.

7 ~~17.~~ (Previously presented) The method according to claim 6 ~~16~~, wherein the subject is from a family that has a member or members with familial Alzheimer's Disease.

8 ~~18.~~ (Previously presented) The method according to claim ~~16~~ 6, wherein the subject is in his or her seventh or eighth decade of life.

19.- 30.(Canceled).